Management ChangeAug 13, 2026, 05:32 PM
Adial Pharma Anticipates CEO & CFO Changes, Board Restructuring
AI Summary
Adial Pharmaceuticals anticipates significant leadership changes, including the termination of current President and CEO Cary Claiborne and CFO Vinay Shah, contingent on stockholder approval at the upcoming 2026 Annual Meeting. Matthew Davidson is expected to become the new President and CEO, and a new CFO will be appointed. Additionally, changes to the Board of Directors are expected. The company also announced its 2026 Annual Meeting will be held on September 17, 2026, and revised deadlines for stockholder proposals to August 23, 2026.
Key Highlights
- Cary Claiborne's employment as President and CEO is anticipated to terminate after the 2026 Annual Meeting, subject to stockholder approval.
- Matthew Davidson, current Chief Development Officer, is anticipated to be appointed President and CEO.
- Vinay Shah's employment as CFO is anticipated to terminate after the 2026 Annual Meeting, subject to stockholder approval.
- A new CFO is anticipated to be appointed following Shah's departure.
- Changes to the Board of Directors' composition and size are anticipated after stockholder approval.
- The 2026 Annual Meeting of Stockholders is scheduled for Thursday, September 17, 2026.
- Revised deadline for stockholder proposals (Rule 14a-8) is August 23, 2026.
- Revised deadline for director nominations or other proposals not under Rule 14a-8 is August 23, 2026.
Price Impact
More from ADIL